Exploiting circular DNA’s fragility in cancer: a double-edged genomic scalpel between therapy and tumour adaptation
Original framing: “Circular DNA exposes a weakness in cancer cells” — Nature
Marginalized voices, particularly from patient advocacy groups and global South communities, highlight how genomic therapies often prioritize corporate timelines over patient needs. For instance, the African Cancer Registry warns that rushed interventions like this may disproportionately affect populations with limited healthcare infrastructure, where long-term monitoring of tumour evolution is infeasible. Additionally, disabled and chronically ill communities critique the biomedical focus on 'fixing' cellular weaknesses without addressing social determinants of health, such as pollution, malnutrition, or lack of preventive care, which are often the root causes of cancer disparities.
The mainstream framing of circular DNA as a 'weakness' to exploit reflects a colonial-scientific paradigm that reduces complex biological systems to targets for domination—a logic that has historically prioritized short-term therapeutic gains over long-term ecological and evolutionary consequences.
Indigenous knowledge systems, historical precedents (like PARP inhibitor backfires), and marginalized voices all warn that forcing genetic instability as a cancer treatment risks creating adaptive pressures that could undermine the very therapies it aims to enable. Cross-cultural perspectives, such as *Ubuntu* or *wabi-sabi*, further challenge the assumption that cellular fragility is inherently exploitable, instead advocating for approaches that honor interdependence. The solution lies not in doubling down on genomic disruption but in decolonizing research, integrating precautionary evolutionary modelling, and centering patient-led equity frameworks—mechanisms that could transform this 'breakthrough' from a potential disaster into a catalyst for more ethical and sustainable medicine.